← All themes

GLP-1 & Obesity

GLP-1 medicines treat obesity and diabetes, and have grown into one of the largest drug categories ever launched. Their reach extends past medicine, because a change in how much people eat moves whole consumer industries.

92 stocks

Obesity Second-Order Effects

#	Name	Funds holding	Growth	Growth %	Fund value
1	1 Pfizer PFE $169B	1,747	-34	-2%	$133B
2	2 Amgen AMGN $238B	1,186	+4	+0.3%	$72.6B
3	3 Eli Lilly LLY $1.13T	1,029	+3	+0.3%	$52.6B
4	4 Becton Dickinson BDX $52.5B	851	+6	+0.7%	$19.2B
5	5 McKesson MCK $116B	815	+14	+2%	$37.1B
6	6 Teva Pharmaceutical Industries Limited TEVA $48.3B	780	+8	+1%	$26B
7	7 Conagra Brands CAG $6.86B	642	+28	+5%	$8.46B
8	8 Novo Nordisk NVO $174B	473	+12	+3%	$8.79B
9	9 DaVita DVA $11.9B	471	-2	-0.4%	$12.9B
10	10 Regeneron Pharmaceuticals REGN $83.1B	448	-5	-1%	$21B
11	11 AstraZeneca AZN $261B	419	+31	+8%	$7.42B
12	12 ResMed RMD $33.9B	313	-6	-2%	$3.87B
13	13 Herbalife HLF $1.53B	288	-20	-6%	$6.35B
14	14 Accendra Health ACH $24.9M	242	-3	-1%	$2.12B
15	15 West Pharmaceutical WST $26.8B	222	-4	-2%	$2.74B
16	16 MannKind Corp MNKD $987M	178	+19	+12%	$1.01B
17	17 Opko Health OPK $1.19B	175	+7	+4%	$735M
18	18 Dr. Reddy's Laboratories RDY $10.8B	169	+4	+2%	$1.12B
19	19 Tootsie Roll Industries TR $2.95B	148	+8	+6%	$415M
20	20 DELISTED WW International WW	148	+11	+8%	$1.19B
21	21 Fresenius Medical Care FMS $11.8B	132	+5	+4%	$454M
22	22 Medifast MED $137M	132	0	0%	$384M
23	ARNA 23 DELISTED Arena Pharmaceuticals Inc ARNA	129	-2	-2%	$628M
24	24 Lexicon Pharmaceuticals LXRX $725M	99	-4	-4%	$749M
25	25 Alaunos Therapeutics TCRT $5.54M	92	-4	-4%	$204M